Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp 120
US5230998A · kind A · utility
17Cited by
0References
7Claims
0Family size
Inventors
Key dates
| Filing date | Jul 25, 1991 |
| Grant date | Jul 27, 1993 |
| Priority date | — |
| Expiry date | Jul 25, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/974
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for the rapid screening of a drug targeted to the V3 hypervariable loop of the human immunodeficiency virus type 1 or type 2 envelope glycoprotein gp 120 comprising measuring the inhibitory effect of the drug on the interaction between gp 120 (or an antigen comprising the V3 hypervariable loop of HIV 1 gp 120 or HIV 2 gp 120) and antibodies specific for the V3 hypervariable loop, and anti-HIV chemotherapy with drugs binding to the V3 hypervariable loop.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.